Published in Neurology on March 28, 2006
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci (2008) 3.78
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One (2013) 1.32
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol (2008) 1.28
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology (2015) 1.21
Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.19
Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One (2012) 1.17
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.16
Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem (2011) 1.10
Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol (2011) 1.07
CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis. PLoS One (2012) 0.98
CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol (2009) 0.96
Neurofilamentopathy in neurodegenerative diseases. Open Neurol J (2011) 0.96
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol (2011) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Review on intermediate filaments of the nervous system and their pathological alterations. Histochem Cell Biol (2013) 0.92
The application of biomarkers in clinical trials for motor neuron disease. Biomark Med (2010) 0.92
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol (2014) 0.90
Topographic regulation of neuronal intermediate filaments by phosphorylation, role of peptidyl-prolyl isomerase 1: significance in neurodegeneration. Histochem Cell Biol (2013) 0.90
CSF markers in amyotrophic lateral sclerosis. J Neural Transm (Vienna) (2012) 0.90
Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve (2009) 0.89
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One (2011) 0.86
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One (2012) 0.86
Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry (2014) 0.86
AxonQuant: A Microfluidic Chamber Culture-Coupled Algorithm That Allows High-Throughput Quantification of Axonal Damage. Neurosignals (2014) 0.84
The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One (2014) 0.83
Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J Neural Transm (Vienna) (2009) 0.83
A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression. Neurol Res Int (2012) 0.82
ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve (2015) 0.81
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics (2015) 0.81
Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 0.81
Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.80
CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol (2015) 0.80
Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? Biomed Res Int (2014) 0.80
Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol (2016) 0.79
The human G93A-SOD1 mutation in a pre-symptomatic rat model of amyotrophic lateral sclerosis increases the vulnerability to a mild spinal cord compression. BMC Genomics (2010) 0.79
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? Int J Mol Sci (2015) 0.79
Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics (2016) 0.78
Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst) (2015) 0.78
Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler (2007) 0.78
Comparative analysis of the time-dependent functional and molecular changes in spinal cord degeneration induced by the G93A SOD1 gene mutation and by mechanical compression. BMC Genomics (2008) 0.77
Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann Clin Transl Neurol (2014) 0.77
Neurofilaments in CSF As Diagnostic Biomarkers in Motor Neuron Disease: A Meta-Analysis. Front Aging Neurosci (2016) 0.75
Cerebrospinal Fluid Levels of Phosphorylated Neurofilament Heavy as a Diagnostic Marker of Canine Degenerative Myelopathy. J Vet Intern Med (2017) 0.75
Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology (2017) 0.75
Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurol (2017) 0.75
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science (1987) 2.48
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology (2012) 2.23
CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology (2001) 2.16
Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology (2004) 2.14
Identification of MYO4, a second class V myosin gene in yeast. J Cell Sci (1994) 2.08
CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology (2010) 1.77
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol (1999) 1.75
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett (1997) 1.71
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology (2011) 1.58
Phenotypic expression of the DYT1 mutation: a family with writer's cramp of juvenile onset. Ann Neurol (1998) 1.53
Transmission of Creutzfeldt-Jakob disease by handling of dura mater. Lancet (1993) 1.52
Skin involvement in amyotrophic lateral sclerosis. Lancet (1996) 1.49
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Proton magnetic resonance spectroscopy in Kennedy syndrome. Arch Neurol (1999) 1.44
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia (2003) 1.37
Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry (2004) 1.35
Preservation of diffusion tensor properties during spatial normalization by use of tensor imaging and fibre tracking on a normal brain database. Phys Med Biol (2007) 1.32
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol (2010) 1.26
A dynein mutation attenuates motor neuron degeneration in SOD1(G93A) mice. Exp Neurol (2006) 1.23
Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol (1995) 1.20
In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke. Neuroreport (2000) 1.18
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm (Vienna) (2004) 1.15
The Bryan cervical disc prosthesis as an alternative to arthrodesis in the treatment of cervical spondylosis: 46 consecutive cases. J Bone Joint Surg Br (2005) 1.15
Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology (1991) 1.13
Novel missense and truncating mutations in FUS/TLS in familial ALS. Neurology (2010) 1.08
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry (2008) 1.08
Precise measurement of the e+e- --> pi+pi-(gamma) cross section with the initial state radiation method at BABAR. Phys Rev Lett (2009) 1.07
Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology (1994) 1.05
Measurement of |V(cb)| and the form-factor slope in B --> Dl- nu(l) decays in events tagged by a fully reconstructed B meson. Phys Rev Lett (2010) 1.05
Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res (2009) 1.05
Small-fiber neuropathy in patients with ALS. Neurology (2011) 1.04
Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther (2005) 1.03
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology (2004) 1.03
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler (2006) 1.02
Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany. Eur J Neurol (2012) 1.01
Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: "chemical preconditioning". J Cereb Blood Flow Metab (1997) 1.01
Lumbar and ventricular CSF protein, leukocytes, and lactate in suspected bacterial CNS infections. Neurology (1998) 1.00
Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm (Vienna) (2007) 1.00
EFNS guidelines on disease-specific CSF investigations. Eur J Neurol (2009) 0.99
Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) (2008) 0.99
Chemical preconditioning: a cytoprotective strategy. Mol Cell Biochem (1997) 0.99
Impact of serum storage conditions on microRNA stability. Leukemia (2012) 0.99
Transient Global Amnesia. Evidence against vascular ischemic etiology from diffusion weighted imaging. J Neurol (2002) 0.99
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler (2007) 0.97
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology (2003) 0.97
Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. Eur J Neurol (2013) 0.96
The ABC-Pyramid Atmospheric Research Observatory in Himalaya for aerosol, ozone and halocarbon measurements. Sci Total Environ (2007) 0.96
Search for the rare leptonic decay B--->tau-nutau. Phys Rev Lett (2005) 0.96
The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J Neuroimmunol (2002) 0.95
Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence. Eur J Neurol (2007) 0.95
CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. Muscle Nerve (2009) 0.95
Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem (2000) 0.95
Is spinal epidural lipomatosis an MRI-based diagnosis with clinical implications? A retrospective analysis. Acta Neurol Scand (2007) 0.94
Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet (2008) 0.93
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler (2012) 0.92
Quantitative ultrasonography in focal neuropathies as compared to clinical and EMG findings. Eur J Ultrasound (1999) 0.92
Imaging and neurochemical markers for diagnosis and disease progression in ALS. J Neurol Sci (2001) 0.91
Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci (2003) 0.91
Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci (1999) 0.91
Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain (2002) 0.91
Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis. Eur J Neurol (2013) 0.90
Studies on the aetiology and pathogenesis of motor neuron diseases. 1. Lathyrism: clinical findings in established cases. Brain (1987) 0.90
Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol (2005) 0.89
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry (1997) 0.89
Cardiomyopathy in motor neuron diseases. J Neurol Neurosurg Psychiatry (2006) 0.89
CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett (2009) 0.89
Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. AJNR Am J Neuroradiol (1999) 0.89
Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur J Pediatr (1991) 0.89
Gender-specificities in Alzheimer's disease and mild cognitive impairment. J Neurol (2008) 0.88
[CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine]. Nervenarzt (2014) 0.88
International Issues: the EAYNT: ten years of unifying European junior neurologists. Neurology (2011) 0.88
High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology (2007) 0.88
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. Neurology (2001) 0.87
Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler (2007) 0.87
The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol (2004) 0.86
Recurrent ptosis. J Neurol Neurosurg Psychiatry (2001) 0.86
The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci (1999) 0.86
[O-Twist Marker for marking breast cancer under neoadjuvant chemotherapy--first results]. Rofo (2007) 0.85
Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol (2000) 0.85
[Clinically atypical CJD: diagnostic relevance of cerebrospinal fluid markers and molecular genetic analysis?]. Dtsch Med Wochenschr (2002) 0.85
Repetitive cerebral bleeding in an adult with Klippel-Trénaunay syndrome. J Neurol (2000) 0.85
Alternative splicing of the 5'-sequences of the mouse EAAT2 glutamate transporter and expression in a transgenic model for amyotrophic lateral sclerosis. J Neurochem (2002) 0.85
Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett (2001) 0.85
White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur J Pediatr (1993) 0.84
Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Res (1999) 0.84
Neurologic diseases associated with use of plant components with toxic potential. Environ Res (1993) 0.84